skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer

Review

(3140) Views  (1211) Full article downloads

Authors: Noemí Reguart, Andrés Felipe Cardona, Rafael Rosell

Published Date June 2010 Volume 2010:2 Pages 143 - 156
DOI: http://dx.doi.org/10.2147/CMAR.S5398

Noemí Reguart1, Andrés Felipe Cardona2, Rafael Rosell3

1Medical Oncology Service, ICMHO, Hospital Clinic Barcelona, Barcelona, Spain; 2Clinical and Translational Oncology Group, Institute of Oncology, Fundación Santa Fe de Bogotá, Bogotá, D.C., Colombia; 3Medical Oncology Service, Catalan Institute of Oncology, ICO, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

Abstract: Erlotinib hydrochloride (Tarceva®) is a member of a class of small molecule inhibitors that targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), with anti-tumor activity in preclinical models. Erlotinib represents a new-generation of agents known as “targeted therapies” designed to act upon cancer cells by interfering with aberrant specific activated pathways needed for tumor growth, angiogenesis and cell survival. Since its approval in November 2004 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior chemotherapy regimen and with a view to improving patients’ outcomes and prevent symptoms, the scientific community has evaluated the potential role of erlotinib in other scenarios such as in maintenance therapy and, in first-line setting for a selected population based on biological markers of response such as mutations of the EGFR. The convenient once-a-day pill administration and the good toxicity profile of erlotinib make it a reasonable candidate for testing in this context. This report provides a review of the role of erlotinib therapy in advanced NSCLC. It summarizes current data and perspectives of erlotinib in upfront treatment and maintenance for advanced NSCLC as well as looking at candidate biomarkers of response to these new targeted-agents.

Keywords: erlotinib, tyrosine kinase inhibitors, first line, maintenance, non-small-cell lung cancer








Readers of this article also read:

Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer
Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics
Emerging treatment options in the management of non-small cell lung cancer
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
The evaluation and optimal use of rituximab in lymphoid malignancies
Phenotype characterization of embryoid body structures generated by a crystal comet effect tail in an intercellular cancer collision scenario
Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University